找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Optimal Use of Sandimmun in Endogenous Uveitis; D. BenEzra,R. B. Nussenblatt,P. Timonen Conference proceedings 1988Latest edition Sandoz L

[復(fù)制鏈接]
樓主: ARSON
11#
發(fā)表于 2025-3-23 10:45:35 | 只看該作者
12#
發(fā)表于 2025-3-23 14:16:02 | 只看該作者
results achieved so far with conventional therapy using systemic corticosteroids and cytotoxic agents, new treatment modalities have been sought. a) Start treatment with Sandimmun at initial doses of During the last four years, a total of over 300 patients 5 mg/kg/day. b) Use Sandimmun in combinatio
13#
發(fā)表于 2025-3-23 21:00:13 | 只看該作者
14#
發(fā)表于 2025-3-23 23:42:02 | 只看該作者
Present Experience with Sandimmun,ine, (97 patients) or placebo (12 patients). Most patients receiving Sandimmun had an initial loading dose of 5 to 10 mg/kg/day followed by a dose reduction according to ocular inflammatory activity and tolerability.
15#
發(fā)表于 2025-3-24 04:39:22 | 只看該作者
Introduction: Endogenous Uveitis, to the iris (iritis), the ciliary body (cyclitis) or both (iridocyclitis), the manifestation is coined anterior uveitis. Localization of the inflammatory reaction to the pars plana and peripheral fundus (pars planitis) as well as vitreous (vitritis) is coined intermediate uveitis, while posterior u
16#
發(fā)表于 2025-3-24 06:38:41 | 只看該作者
Conference proceedings 1988Latest editionndent studies all over the d) Taper Sandimmun dose as rapidly as possible to a world (over 200 patients) and in a masked manner in 4 maintenance dose below 5 mg/kg/day. e) Do not discontinue treatment with Sandimmun rap- independent controlled studies (over 100 patients re- idly.
17#
發(fā)表于 2025-3-24 12:24:38 | 只看該作者
18#
發(fā)表于 2025-3-24 15:51:40 | 只看該作者
19#
發(fā)表于 2025-3-24 20:32:39 | 只看該作者
D. BenEzra M.D., Ph.D.,R. B. Nussenblatt M.D.,P. Timonen M.B.
20#
發(fā)表于 2025-3-25 00:38:40 | 只看該作者
D. BenEzra M.D., Ph.D.,R. B. Nussenblatt M.D.,P. Timonen M.B.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 14:34
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
太白县| 利川市| 崇阳县| 兴安县| 苏尼特右旗| 龙岩市| 普安县| 剑阁县| 安新县| 丰都县| 山东| 巫溪县| 中超| 文登市| 个旧市| 德清县| 佛山市| 双鸭山市| 那坡县| 鹤岗市| 将乐县| 金昌市| 昌黎县| 彝良县| 黄陵县| 邢台县| 盐山县| 黑山县| 兴城市| 长寿区| 曲靖市| 治多县| 浦江县| 湖北省| 通城县| 厦门市| 黑龙江省| 孝感市| 桐柏县| 遂宁市| 绍兴市|